MG
TNXP icon

Michael Gelband’s Tonix Pharmaceuticals TNXP Stock Holding History

Michael Gelband’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– -$239K – 2638
2021
Q2 		– Sell
-1
Closed -$735K – 1885
2021
Q1 		$762K Buy
+1
New +$765K 0.01% 1083

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's TNXP Position: Q3 2021 in Review

Michael Gelband held its Tonix Pharmaceuticals (TNXP) position steady in Q3 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Michael Gelband first reported a position in TNXP in Q1 2021 and has held it in 1 quarter since. The position peaked at $762K in Q1 2021. 18 funds tracked by Wall St. Rank hold TNXP as of Q3 2021.

  • Michael Gelband held 0 shares of Tonix Pharmaceuticals worth $0 as of Q3 2021.
  • Michael Gelband left its Tonix Pharmaceuticals share count unchanged in Q3 2021.
  • Tonix Pharmaceuticals made up ﹤0.01% of Michael Gelband's portfolio in Q3 2021, its #2638 holding.
  • Michael Gelband first reported a position in Tonix Pharmaceuticals in Q1 2021 and has held it in 1 quarter since.
  • Michael Gelband's Tonix Pharmaceuticals position peaked at $762K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.